Despite initial treatment success, most myeloma patients eventually develop drug resistance. In addition to genetic mutations, non-genetic changes in cell states play a crucial role in this process. The project utilizes cutting-edge single-cell technologies to investigate how myeloma cells respond to therapy and identify the mechanisms driving resistance. By analyzing the chromatin landscape and gene regulatory networks, the scientists aim to discover novel therapeutic targets that could help improve treatment strategies and overcome resistance.